Multi-organ Radiomics-Based Prediction of Future Remnant Liver Hypertrophy Following Portal Vein Embolization

Multi-region nomogram for predicting central lymph node metastasis in papillary thyroid carcinoma using multimodal imaging: A multicenter study

BACKGROUND AND OBJECTIVE

Central lymph node metastasis (CLNM) is associated with high recurrence rate and low survival in patients with papillary thyroid carcinoma (PTC). However, there is no satisfactory model to predict CLNM in PTC. This study aimed to integrate PTC deep learning feature based on ultrasound (US) images, fat radiomics features based on computed tomography (CT) images and clinical characteristics to construct a multimodal and multi-region nomogram (MMRN) for predicting the CLNM in PTC.

METHODS

We enrolled 661 patients diagnosed with PTC by thyroidectomy from two independent centers. Patients were divided into the primary cohort, internal test cohort (ITC), and external test cohort (ETC), and collected their US images and CT images. Resnet50 was employed to predict the CLNM status of PTC based on US images. Using radiomics feature extraction methods to extract fat radiomics features from CT images. Feature selection was conducted using the least absolute shrinkage and selection operator (LASSO) regression. The predictive performance of the MMRN was evaluated using five-fold cross-validation. We comprehensively evaluated the DLRCN and compared it with five radiologists.

RESULTS

In the ITC and ETC, the area under the curves (AUCs) of MMRN were 0.829 (95 % CI: 0.822, 0.835) and 0.818 (95 % CI: 0.808, 0.828). The calibration curve revealed good predictive accuracy between the actual probability and predicted probability (P > 0.05). Decision curve analysis showed that the MMRN was clinically useful. Under equal specificity or sensitivity, the performance of MMRN increased by 6.5 % or 2.9 % compared to radiologist assessments. The incorporation of fat radiomics features led to significant net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI=0.174, P < 0.05, IDI=0.035, P < 0.05).

CONCLUSION

The MMRN demonstrated good performance in predicting the CLNM status of PTC, which was comparable to radiologist assessments. The fat radiomics features exhibited supplementary value for predicting CLNM in PTC.

Development and External Validation of a Combined Clinical-Radiomic Model for Predicting Insufficient Hypertrophy of the Future Liver Remnant following Portal Vein Embolization

OBJECTIVES

This study aimed to develop and externally validate a model for predicting insufficient future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) based on clinical factors and radiomics of pretreatment computed tomography (CT) PATIENTS AND METHODS: Clinical information and CT scans of 241 consecutive patients from three Swedish centers were retrospectively collected. One center (120 patients) was applied for model development, and the other two (59 and 62 patients) as test cohorts. Logistic regression analysis was adopted for clinical model development. A FLR radiomics signature was constructed from the CT images using the support vector machine. A model combining clinical factors and FLR radiomics signature was developed. Area under the curve (AUC) was adopted for predictive performance evaluation RESULTS: Three independent clinical factors were identified for model construction: pretreatment standardized FLR (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04-1.20), alanine transaminase (ALT) level (OR: 0.98, 95% CI: 0.97-0.99), and PVE material (OR: 0.27, 95% CI: 0.08-0.87). This clinical model showed an AUC of 0.75, 0.71, and 0.68 in the three cohorts, respectively. A total of 833 radiomics features were extracted, and after feature dimension reduction, 16 features were selected for FLR radiomics signature construction. When adding it to the clinical model, the AUC of the combined model increased to 0.80, 0.76, and 0.72, respectively. However, the increase was not significant.

CONCLUSIONS

Pretreatment CT radiomics showed added value to the clinical model for predicting FLR hypertrophy following PVE. Although not reaching statistically significant, the evolving radiomics holds a potential to supplement traditional predictors of FLR hypertrophy.

Radiomics for Treatment Planning in Liver Cancers

This Surgical Innovation delves into the transformative potential of radiomics in liver cancer treatment, highlighting its advancements in pretreatment prognosis, noninvasive tumor profiling, and treatment response prediction, thus paving the way for more personalized therapeutic strategies.